StreetInsider.com News Articles

AbbVie presents long-term IBD drug data at European gastroenterology meeting

Sat, 17 Oct 2026 08:17:59 -0400

AbbVie (NYSE: ABBV) presented 20 scientific abstracts from its inflammatory bowel disease portfolio at the 2026 United European Gastroenterology Week, held October 17-20 in Barcelona, Spain, according to a company statement.

Data from the COMMAND study showed risankizumab (Skyrizi) produced sustained clinical and endoscopic outcomes in ulcerative colitis patients over three years. At week 96, as-observed clinical remission rates ranged from 54.0% to 73.1%, and endoscopic remission rates ranged from 38.8% to 53.5% across advanced therapy-naïve and experienced patients receiving 180mg.

For Crohn's disease, upadacitinib (Rinvoq) data from the U-ENDURE long-term extension study showed clinical and endoscopic outcomes maintained through approximately four

AbbVie presents long-term IBD drug data at European gastroenterology meeting

Sat, 17 Oct 2026 08:17:59 -0400

For Crohn's disease, upadacitinib (Rinvoq) data from the U-ENDURE long-term extension study showed clinical and endoscopic outcomes maintained through approximately four

SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

Sat, 17 Oct 2026 02:00:00 -0400

20 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programs
Latest long-term and real-world data with SKYRIZI^®(risankizumab) and RINVOQ^® (upadacitinib) provide additional insight into clinical and endoscopic outcomes over approximately three years in moderately to severely active Crohn's disease

SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

Sat, 17 Oct 2026 02:00:00 -0400

20 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programs

Latest long-term and real-world data with SKYRIZI^®(risankizumab) and RINVOQ^® (upadacitinib) provide additional insight into clinical and endoscopic outcomes over approximately three years in moderately to severely active Crohn's disease

AbbVie expands board to 13, appoints UC San Diego health chief

Thu, 15 Oct 2026 16:03:48 -0400

AbbVie Inc. (NYSE: ABBV) expanded its Board of Directors from 12 to 13 members on October 14, 2026, appointing Dr. John M. Carethers as a Class II director.
Dr. Carethers currently serves as Vice Chancellor for Health Sciences at the University of California San Diego and previously served as a director of Avantor, Inc. He has been appointed to AbbVie's Public Policy and Sustainability Committee.
The board determined that Dr. Carethers qualifies as an independent director under the New York Stock Exchange Listed Company Manual standards and AbbVie's own governance guidelines. His compensation as an independent director will follow the terms disclosed

AbbVie expands board to 13, appoints UC San Diego health chief

Thu, 15 Oct 2026 16:03:48 -0400

AbbVie Inc. (NYSE: ABBV) expanded its Board of Directors from 12 to 13 members on October 14, 2026, appointing Dr. John M. Carethers as a Class II director.
Dr. Carethers currently serves as Vice Chancellor for Health Sciences at the University of California San Diego and previously served as a director of Avantor, Inc. He has been appointed to AbbVie's Public Policy and Sustainability Committee.
The board determined that Dr. Carethers qualifies as an independent director under the New York Stock Exchange Listed Company Manual standards and AbbVie's own governance guidelines. His compensation as an independent director will follow the terms disclosed

Form 8-K AbbVie Inc. For: Oct 14

Thu, 15 Oct 2026 16:01:00 -0400
si-local-file:///var/storage/secattach/20261015/27193265.html

AbbVie Skyrizi shows endoscopic gains in Crohn's disease trial

Tue, 13 Oct 2026 15:15:17 -0400

AbbVie (NYSE: ABBV) presented new data from its Phase 3 AFFIRM study at the American College of Gastroenterology 2026 Annual Scientific Meeting, showing endoscopic outcomes for subcutaneous risankizumab (Skyrizi) in adults with moderately to severely active Crohn's disease.

At week 24, 35.8% of patients treated with subcutaneous Skyrizi achieved endoscopic remission, compared with 9.1% in the placebo group. Ulcer-free endoscopy was achieved by 36.6% of Skyrizi-treated patients with ulcers at baseline, versus 9.1% on placebo. Among advanced therapy-naïve patients, rates were higher, with 45.1% achieving endoscopic remission and 49.0% achieving ulcer-free endoscopy.

The study enrolled 289 patients randomized in a 2:1 ratio

AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease

Tue, 13 Oct 2026 15:15:00 -0400

Higher rates of endoscopic remission and ulcer-free endoscopy were observed following subcutaneous SKYRIZI^®(risankizumab-rzaa)treatment versus placeboⁱ

Results build on previously reported week 12 findings in which SKYRIZI achieved superiority in the co-primary endpoints of clinical remission and endoscopic response versus placebo

AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease

Tue, 13 Oct 2026 15:15:00 -0400

Higher rates of endoscopic remission and ulcer-free endoscopy were observed following subcutaneous SKYRIZI^®(risankizumab-rzaa)treatment versus placeboⁱ

Results build on previously reported week 12 findings in which SKYRIZI achieved superiority in the co-primary endpoints of clinical remission and endoscopic response versus placebo

New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease

Sun, 11 Oct 2026 13:00:00 -0400

New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints and observed subgroups

New open-label extension analyses demonstrate sustained endoscopic outcomes over time with SKYRIZI, even in patients with

New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease

Sun, 11 Oct 2026 13:00:00 -0400

New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints and observed subgroups

New open-label extension analyses demonstrate sustained endoscopic outcomes over time with SKYRIZI, even in patients with

Abbvie (ABBV) PT Raised to $275 at UBS

Fri, 09 Oct 2026 09:06:16 -0400
UBS analyst Michael Yee raised the price target on Abbvie (NYSE: ABBV) to $275.00 (from $260.00) while maintaining a Neutral rating.

Abbvie (ABBV) PT Raised to $300 at JPMorgan

Thu, 08 Oct 2026 08:09:12 -0400
JPMorgan analyst Chris Schott raised the price target on Abbvie (NYSE: ABBV) to $300.00 (from $285.00) while maintaining a Overweight rating.

Abbvie (ABBV) PT Raised to $290 at Cantor Fitzgerald

Thu, 08 Oct 2026 07:10:20 -0400

Cantor Fitzgerald analyst Carter Gould raised the price target on Abbvie (NYSE: ABBV) to $290.00 (from $285.00) while maintaining an Overweight rating.
The analyst commented, "Skyrizi / Rinvoq scripts are tracking below consensus, only adding to questions around whether each product can drive upside over 2H and justify another guidance raise. While ABBV has done considerable work to address I&I durability into the 2030s, Skyrizi commercial performance remains critical to the narrative (even ahead of the sc Crohn’s label update). Mixed views on forthcoming lutikizumab HS data also keep this a 2-way debate."

Abbvie (ABBV) PT Raised to $290 at Cantor Fitzgerald

Thu, 08 Oct 2026 07:10:20 -0400

Cantor Fitzgerald analyst Carter Gould raised the price target on Abbvie (NYSE: ABBV) to $290.00 (from $285.00) while maintaining an Overweight rating.
The analyst commented, "Skyrizi / Rinvoq scripts are tracking below consensus, only adding to questions around whether each product can drive upside over 2H and justify another guidance raise. While ABBV has done considerable work to address I&I durability into the 2030s, Skyrizi commercial performance remains critical to the narrative (even ahead of the sc Crohn’s label update). Mixed views on forthcoming lutikizumab HS data also keep this a 2-way debate."

FDA grants AbbVie's Temab-A two breakthrough therapy designations

Wed, 07 Oct 2026 08:32:45 -0400

AbbVie (NYSE: ABBV) announced that the U.S. Food and Drug Administration has granted two Breakthrough Therapy Designations for telisotuzumab adizutecan, known as Temab-A, in colorectal cancer and non-small cell lung cancer.
The first designation covers Temab-A in combination with bevacizumab for adults with refractory, metastatic colorectal cancer who have previously received fluoropyrimidine, irinotecan, oxaliplatin, anti-VEGF monoclonal antibody, and if indicated, anti-EGFR monoclonal antibody therapy. The second designation is for Temab-A as a monotherapy for adults with locally advanced or metastatic EGFR wild-type, c-Met protein-expressing, non-squamous NSCLC who have previously received platinum-based chemotherapy and an anti-PD-(L)1 antibody therapy.
Both designations were based primarily

FDA grants AbbVie's Temab-A two breakthrough therapy designations

Wed, 07 Oct 2026 08:32:45 -0400

AbbVie (NYSE: ABBV) announced that the U.S. Food and Drug Administration has granted two Breakthrough Therapy Designations for telisotuzumab adizutecan, known as Temab-A, in colorectal cancer and non-small cell lung cancer.
The first designation covers Temab-A in combination with bevacizumab for adults with refractory, metastatic colorectal cancer who have previously received fluoropyrimidine, irinotecan, oxaliplatin, anti-VEGF monoclonal antibody, and if indicated, anti-EGFR monoclonal antibody therapy. The second designation is for Temab-A as a monotherapy for adults with locally advanced or metastatic EGFR wild-type, c-Met protein-expressing, non-squamous NSCLC who have previously received platinum-based chemotherapy and an anti-PD-(L)1 antibody therapy.
Both designations were based primarily

AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC

Wed, 07 Oct 2026 08:30:00 -0400

Temab-A is an investigational, next-generation, c-Met-directed antibody-drug conjugate (ADC) with a novel topoisomerase 1 inhibitor (Top1i) being studied in advanced solid tumors including colorectal cancer (CRC) and non-small cell lung cancer (NSCLC)

These designations represent the first Breakthrough Therapy Designations (BTDs) for Temab-A and further underscore the

AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC

Wed, 07 Oct 2026 08:30:00 -0400

Temab-A is an investigational, next-generation, c-Met-directed antibody-drug conjugate (ADC) with a novel topoisomerase 1 inhibitor (Top1i) being studied in advanced solid tumors including colorectal cancer (CRC) and non-small cell lung cancer (NSCLC)

These designations represent the first Breakthrough Therapy Designations (BTDs) for Temab-A and further underscore the

Abbvie (ABBV) PT Raised to $310 at Morgan Stanley

Wed, 07 Oct 2026 07:57:57 -0400
Morgan Stanley analyst Terrance Flynn raised the price target on Abbvie (NYSE: ABBV) to $310.00 (from $296.00) while maintaining a Overweight rating.

UBS Reiterates Neutral Rating on Abbvie (ABBV)

Tue, 06 Oct 2026 09:11:57 -0400

UBS analyst Michael Yee reiterated a Neutral rating and $260.00 price target on Abbvie (NYSE: ABBV).
The analyst commented, "ABBV and GMAB announced results from the Phase III study of Epkinly (CD20 T-cell engager) in frontline DLBCL in combination with standard-of-care R-CHOP chemotherapy. The data shows a 0.49 HR for the Epkinly + R-CHOP combination vs. the comparator arm of R-CHOP alone -- which we think is strong and would support 1L use in combination with R-CHOP potentially as a preferred agent over other 1L regimens that have recently shown positive data (Polivy, glofitimab). We note that the Roche Polivy (anti CD79b ADC) previously beat R-CHOP as well

Abbvie (ABBV) PT Raised to $320 at Scotiabank

Tue, 06 Oct 2026 08:10:10 -0400
Scotiabank analyst Louis Chen raised the price target on Abbvie (NYSE: ABBV) to $320.00 (from $280.00) while maintaining a Sector Outperform rating.

Genmab stock surges 11% on positive cancer drug trial data

Mon, 05 Oct 2026 16:30:51 -0400

Investing.com -- Genmab A/S (NASDAQ:GMAB) shares rose 11% Monday afternoon following the announcement of positive topline results from a Phase 3 trial of epcoritamab in combination with R-CHOP for newly diagnosed diffuse large B-cell lymphoma patients.

The EPCORE DLBCL-2 trial, conducted with AbbVie (NYSE:ABBV), demonstrated a statistically significant improvement in progression-free survival for patients with an International Prognostic Index score of 2 to 5. The trial showed a 51% reduction in the risk of disease progression or death, with a hazard ratio of 0.49.

This marks the first Phase 3 study of a bispecific antibody combination therapy to

Genmab stock surges 11% on positive cancer drug trial data

Mon, 05 Oct 2026 16:30:51 -0400

Investing.com -- Genmab A/S (NASDAQ:GMAB) shares rose 11% Monday afternoon following the announcement of positive topline results from a Phase 3 trial of epcoritamab in combination with R-CHOP for newly diagnosed diffuse large B-cell lymphoma patients.

The EPCORE DLBCL-2 trial, conducted with AbbVie (NYSE:ABBV), demonstrated a statistically significant improvement in progression-free survival for patients with an International Prognostic Index score of 2 to 5. The trial showed a 51% reduction in the risk of disease progression or death, with a hazard ratio of 0.49.

This marks the first Phase 3 study of a bispecific antibody combination therapy to